Farmas USA

Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014

http://boardvote.com/symbol/AMRN/communique/727843

AMRN

Una de patentes

Horizon Pharma Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering VIMOVO(R) (Naproxen / Esomeprazole) Delayed Release Tablets

http://boardvote.com/symbol/HZNP/communique/727910

HZNP

FLML consigue la exclusividad de su fármaco.

LYON, FRANCE--(Marketwired - Aug 4, 2014) - Flamel Technologies S.A. (NASDAQ: FLML) has received communication from the U.S. Food and Drug Administration (FDA) that all manufacturers of unapproved versions of neostigmine methylsulfate have been notified by the FDA to cease manufacturing of the unapproved product as of July 30, 2014. Current inventory in the channel of the unapproved product can continue to be sold. Flamel has not been provided with information on the inventory levels held by these manufacturers.

"We sincerely appreciate the communication from the FDA which clearly indicates their commitment to the integrity of the unapproved drugs initiative. Our inventories are sufficient to provide 100% of the market demand for neostigmine methylsulfate with Bloxiverz™, the only approved FDA-approved version of the product in the market," said Mike Anderson, Chief Executive Officer of Flamel.

Baxs

Sólo mil acciones pero da gustito ver +25% en el pre

cosa de patentes

http://www.marketwatch.com/story/baxano-surgical-inc-announces-two-new-patents-for-veo-direct-lateral-and-axialif-minimally-invasive-interbody-fusion-systems-2014-08-05?reflink=MW_news_stmp

BAXS

HZNP

Sí, pero por lo que leo la patente corresponde a Pozen (tícker: POZN), no a HZNP directamente. No sé de qué va el tema.

BAXS

Dudo que lo aguante.

Baxs

Aún no he visto nada de los earnings. Eran ayer no?